Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

News

Health Care

General

Nutriband Provides An Update On Its Aversa Fentanyl Product Development Program As It Aims To Complete Scale-up Of The Commercial Manufacturing Process And Move Towards The Single Phase 1 Human Abuse Potential Study Before FDA Application Filing - Nutriband (NASDAQ:NTRB)

Benzinga Newsdesk

Nutriband

NTRB

Nutriband Provides An Update On Its Aversa Fentanyl Product Development Program As It Aims To Complete Scale-up Of The Commercial Manufacturing Process And Move Towards The Single Phase 1 Human Abuse Potential Study Before FDA Application Filing

Comments